Alpine Immune Sciences (NASDAQ:ALPN)‘s stock had its “buy” rating restated by stock analysts at $1 in a note issued to investors on Tuesday. They presently have a $13.00 price target on the biotechnology company’s stock. $1’s target price indicates a potential upside of 132.56% from the stock’s current price.
The analysts wrote, “Monday, Alpine announced that dosing has commenced in a Phase 1 healthy volunteer trial (HV) of ALPN-101, a dual blocker of CD28 and ICOS based on Alpine’s variant immunoglobulin domain (vIgD) platform technology. ALPN-101 is the first vIgD-based therapy to enter the clinic, and we view the initiation as an important milestone. We believe ALPN-101 has the potential to become a best-in- class therapy in multiple inflammatory and autoimmune disorders, including graft- versus-host disease (GVHD). Preliminary results from the HV study could be available in 2H19, and exploratory biomarker analyses in the trial protocol could help inform ALPN-101’s development strategy. The company is on track to file a second IND for its oncology-focused ALPN-202 program in 1H19. Reiterate Outperform, $13 PT.””
ALPN has been the topic of several other research reports. Zacks Investment Research downgraded shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a report on Friday, January 11th. ValuEngine cut shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. Finally, Oppenheimer set a $13.00 price objective on shares of Alpine Immune Sciences and gave the stock a “buy” rating in a report on Monday, November 12th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $12.00.
Alpine Immune Sciences stock opened at $5.59 on Tuesday. The company has a market capitalization of $78.39 million, a price-to-earnings ratio of -4.66 and a beta of 2.11. The company has a quick ratio of 9.20, a current ratio of 9.20 and a debt-to-equity ratio of 0.05. Alpine Immune Sciences has a 12 month low of $3.66 and a 12 month high of $10.57.
In related news, insider Mitchell Gold acquired 190,875 shares of Alpine Immune Sciences stock in a transaction that occurred on Friday, January 18th. The stock was purchased at an average price of $5.37 per share, for a total transaction of $1,024,998.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James N. Topper bought 372,439 shares of Alpine Immune Sciences stock in a transaction dated Friday, January 18th. The shares were purchased at an average cost of $5.37 per share, for a total transaction of $1,999,997.43. The disclosure for this purchase can be found here. Corporate insiders own 69.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in Alpine Immune Sciences by 122.2% during the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 18,052 shares in the last quarter. Hikari Power Ltd purchased a new stake in shares of Alpine Immune Sciences in the 4th quarter worth about $453,000. Victory Capital Management Inc. boosted its stake in shares of Alpine Immune Sciences by 109.0% during the 4th quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock valued at $501,000 after buying an additional 70,980 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Alpine Immune Sciences by 20.9% during the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after acquiring an additional 21,124 shares during the period. Finally, Vanguard Group Inc increased its position in Alpine Immune Sciences by 5.2% in the 3rd quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares during the period. Institutional investors and hedge funds own 56.14% of the company’s stock.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.